Exclusive special offer and discount title banner vector image

GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Global Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, Other Drug Types) Market by Type (Prescription, OTC) Market by Route of Administration (Topical, Oral, Injectable) by Geography


MARKET OVERVIEW

The global psoriatic arthritis treatment market was valued at $xx billion in 2022 and is expected to reach $xx billion by 2032, growing at a CAGR of 7.64% during the forecast period 2023-2032

Psoriatic arthritis (PsA) is a chronic inflammatory condition with no cure. It is caused by a combination of genetic and environmental factors. Joint stiffness and soreness, swelling in the fingers and toes, decreased range of motion, exhaustion, and nail abnormalities are some of the symptoms of PsA. 

Psoriatic arthritis (PsA) can occasionally impact the skin, eyes, and other organs. It most commonly develops between the ages of 30 and 50. According to National Psoriasis Foundation, 2%-3% of the total population currently suffers from psoriasis and 30% among these suffer from psoriatic arthritis. 

The global psoriatic arthritis treatment market comprises drugs and treatments specifically approved for treating PsA alongside treatment modalities like NSAIDs, DMARDs, physical therapy, and other supportive treatments.

Read our latest blog on the Psoriatic Arthritis Treatment Market

GROWTH ENABLERS

Key growth enablers of the global psoriatic arthritis treatment market are:

  • Rising prevalence of psoriatic arthritis
  • Advancements in treatment options
    • Biologic drugs have completely revolutionized psoriatic arthritis treatment. For instance, TNF and IL-17 inhibitors are biological drugs that considerably reduce the disease’s symptoms and development among patients. These drugs target particular immune system proteins that are responsible for inflammation.
    • Other advancements, like small molecule drugs, work by inhibiting the particular enzymes involved in inflammation and the immune response.
    • Combination therapy and lifestyle modifications have also contributed to dealing with and managing the symptoms. 
  • Favorable reimbursement policies

GROWTH RESTRAINTS

Key growth restraining factors of the global psoriatic arthritis treatment market are:

  • High treatment costs
  • Treatment for psoriatic arthritis can be expensive, especially when using biological medications, as these drugs are administered in a clinical setting, which can be highly expensive. This may restrict patients’ access to care, especially in underdeveloped nations or for those with inadequate insurance.
  • Many medications for psoriatic arthritis are covered by patents and market exclusivity agreements, which stop other producers from creating generic treatment versions. The cost of the medication may increase due to the absence of competition.
  • Adverse effects of medications
  • Limited patient awareness about treatment availability

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Psoriatic Arthritis Treatment Market | Top Trends

  • Technological advancements, such as new diagnostic instruments and imaging methods, result in a quicker and more precise diagnosis of psoriatic arthritis. This leads to better patient outcomes and increased demand for efficient therapy.
  • The market is expanding due to continuous investment in PsA treatment research and development, producing new, more potent medicines. For instance, the National Institutes of Health (NIH), the main federal agency in charge of biomedical research in the United States, finances numerous PsA-related studies. These studies address a variety of subjects, including the genetics of the illness, the efficacy of various therapeutic options, and the influence of dietary and lifestyle choices on disease development.

MARKET SEGMENTATION

Market Segmentation – Drug Type, Type, and Route of Administration –

Market by Drug Type: 

  • NSAIDs
  • DMARDs
  • DMARDs are the most preferred medications for treating psoriatic arthritis as they address the underlying inflammation and immune system dysfunction responsible for PsA.
  • DMARDs can delay or halt joint deterioration and deformity compared to painkillers and anti-inflammatory drugs that merely offer symptomatic relief.
  • The American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) declared biologics as the preferred treatment for this disease. Biologics are identified as a type of DMARD made of living organisms and proteins. This drug targets specific inflammation-causing parts of the immune system.
  • Biologics
  • Other Drug Types

 

Market by Type:

  • Prescription
  • Prescription drugs are preferred over OTC drugs as prescription drugs are designed to target specific inflammation and immune system dysfunction. In contrast, OTC drugs do not address the underlying causes of the disease.
  • Prescription drugs include DMARDs and biologic drugs specifically prescribed by a healthcare provider.
  • OTC

Market by Route of Administration:

  • Topical
  • Oral
  • Injectable

GEOGRAPHICAL STUDY

Geographical Study Based on Four Major Regions:

  • North America: The United States, Canada
    • North America’s psoriatic arthritis treatment market is estimated to garner the largest revenue share during the forecast period due to the growing number of psoriatic arthritis patients. 
    • Healthcare affordability in the US, awareness among the people, and technological advancements have contributed to the region’s dominance.
    • Speedy psoriatic arthritis drug approvals by US FDA are also propelling the market in North America. 
  • Europe: The United Kingdom, France, Germany, Spain, Italy, Poland, Belgium, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of the World: Latin America, the Middle East, and Africa

MAJOR PLAYERS

The major players in the global psoriatic arthritis treatment market are:

  • Amgen Inc
  • Bristol-Myers Squibb Company
  • Eli Lily and Company
  • Johnson & Johnson
  • Novartis AG
  • Abbvie Inc

Key strategies adopted by some of these companies:

  • January 2022: The US Food and Drug Administration (FDA) approved the second indication of AbbVie’s SKYRIZI for treating adults with active psoriatic arthritis (PsA). Prescription medicine is to be taken per the healthcare provider’s prescription. 
  • August 2022: The US Food and Drug Administration (FDA) approved STELARA® for treating older individuals with active psoriatic arthritis (PsA), according to a press release from Johnson & Johnson’s Janssen Pharmaceutical Companies.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedDrug Type, Type, Route of Administration
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed

Amgen Inc, Bristol-Myers Squibb Company, Eli Lily and Company, Johnson & Johnson, Novartis AG, AbbVie Inc

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISING PREVALENCE OF PSORIATIC ARTHRITIS  
      2. ADVANCEMENTS IN TREATMENT OPTIONS
      3. FAVORABLE REIMBURSEMENT POLICIES 
    2. KEY RESTRAINTS
      1. HIGH TREATMENT COSTS
      2. ADVERSE EFFECTS OF MEDICATIONS
      3. LIMITED PATIENT AWARENESS ABOUT TREATMENT AVAILABILITY
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR UNITED STATES
      2. GROWTH PROSPECT MAPPING FOR FRANCE
      3. GROWTH PROSPECT MAPPING FOR JAPAN
      4. GROWTH PROSPECT MAPPING FOR LATIN AMERICA
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
  5. MARKET BY DRUG TYPE
    1. NSAIDS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. DMARDS
      1. MARKET FORECAST FIGURES
      2. SEGMENT ANALYSIS
    3. BIOLOGICS
      1. MARKET FORECAST FIGURES
      2. SEGMENT ANALYSIS
    4. OTHER DRUG TYPES
      1. MARKET FORECAST FIGURES
      2. SEGMENT ANALYSIS
  6. MARKET BY TYPE
    1. PRESCRIPTION
      1. MARKET FORECAST FIGURES
      2. SEGMENT ANALYSIS
    2. OTC
      1. MARKET FORECAST FIGURES
      2. SEGMENT ANALYSIS
  7. MARKET BY ROUTE OF ADMINISTRATION
    1. TOPICAL
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. ORAL
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. INJECTABLE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET DRIVERS
      3. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET CHALLENGES
      4. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET
      6. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET DRIVERS
      3. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET CHALLENGES
      4. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET
      6. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        6. BELGIUM
          1. BELGIUM PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
      7. POLAND
        1. POLAND PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        1. REST OF EUROPE
          1. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET DRIVERS
      3. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET CHALLENGES
      4. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET
      6. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET DRIVERS
      3. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET CHALLENGES
      4. REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET
      6. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. ABBVIE INC
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      2. AMGEN INC
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      3. BRISTOL-MYERS SQUIBB COMPANY
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      4. ELI LILY AND COMPANY
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      5. JOHNSON & JOHNSON
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      6. MERC & CO INC
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      7. MYLAN NV
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      8. NOVARTIS AG
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      9. PFIZER INC
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      10. UCB SA
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – PSORIATIC ARTHRITIS TREATMENT 

TABLE 2: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: GLOBAL NSAIDS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL NSAIDS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: GLOBAL DMARDS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL DMARDS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: GLOBAL BIOLOGICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL BIOLOGICS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 12: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 14: GLOBAL PRESCRIPTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL PRESCRIPTION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 16: GLOBAL OTC MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL OTC MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 18: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 20: GLOBAL TOPICAL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL TOPICAL MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 22: GLOBAL ORAL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL ORAL MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 24: GLOBAL INJECTABLE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL INJECTABLE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 26: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 28: NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 30: NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK

TABLE 31: KEY PLAYERS OPERATING IN NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET

TABLE 32: EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 33: EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 34: EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK

TABLE 35: KEY PLAYERS OPERATING IN EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET

TABLE 36: ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 37: ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 38: ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK

TABLE 39: KEY PLAYERS OPERATING IN ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET

TABLE 40: REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 41: REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 42: REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET REGULATORY FRAMEWORK

TABLE 43: KEY PLAYERS OPERATING IN REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET

TABLE 44: LIST OF MERGERS & ACQUISITIONS

TABLE 45: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 46: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 47: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES 

FIGURE 4: GROWTH PROSPECT MAPPING FOR FRANCE

FIGURE 5: GROWTH PROSPECT MAPPING FOR JAPAN

FIGURE 6: GROWTH PROSPECT MAPPING FOR LATIN AMERICA

FIGURE 7: MARKET MATURITY ANALYSIS

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2022

FIGURE 10: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY NSAIDS, 2023-2032 (IN $ MILLION)

FIGURE 11: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DMARDS, 2023-2032 (IN $ MILLION)

FIGURE 12: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY BIOLOGICS, 2023-2032 (IN $ MILLION)

FIGURE 13: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY OTHER DRUG TYPES, 2023-2032 (IN $ MILLION)

FIGURE 14: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 15: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)

FIGURE 16: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY OTC, 2023-2032 (IN $ MILLION)

FIGURE 17: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, GROWTH POTENTIAL, BY ROUTE OF ADMINISTRATION, IN 2022

FIGURE 18: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TOPICAL, 2023-2032 (IN $ MILLION)

FIGURE 19: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ORAL, 2023-2032 (IN $ MILLION)

FIGURE 20: GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY INJECTABLE, 2023-2032 (IN $ MILLION)

FIGURE 21: NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 22: UNITED STATES PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 23: CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 24: EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 25: UNITED KINGDOM PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 26: GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 27: FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 28: ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 29: SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 30: BELGIUM PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 31: POLAND PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 32: REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 33: ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 34: CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 35: JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 36: INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 37: SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 38: INDONESIA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: THAILAND PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 40: VIETNAM PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 41: AUSTRALIA & NEW ZEALAND PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 42: REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 43: REST OF WORLD PSORIATIC ARTHRITIS TREATMENT MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 44: LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FIGURE 45: MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

Some of the common side effects of psoriatic arthritis medications include stomach pain, nausea, dizziness, increased risk of infection, and liver damage.

Yes, dietary and exercise modifications can help manage the symptoms of psoriatic arthritis. Although altering one’s lifestyle can help manage psoriatic arthritis symptoms, this type of care should not be substituted.

Commonly prescribed medications for psoriatic arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, and biologic agents.